Request Demo
Sun Pharma seals partnership with AstraZeneca to market SZC second brand in India
License out/inDrug Approval
Mumbai:
Indian pharma
major Sun Pharmaceuticals has inked a second brand partnership with
AstraZSun Pharmaceuticals
AstraZenecao sell
Sodium Zirconium Cyclosilicate
SZC
) brand in the country.
According to the announcement, the innovator will market the therapy under the global brand name
Lokelma
Lokelma the Mumbai–based drugmaker will promote and distribute the therapy as Gimliand.
Under the agreement
AstraZeneca
AstraZeneca the intellectual property rights to
SZC
and hold the Marketing Authorization along with the import license of the molecule.
The financial terms of the agreement and the therapy's market price have not been disclosed.
SZC, is a non-absorbed, inorganic, potassium-binding crystalline compound used to treat
SZCerkalemia
hyperkalemia of potassium in the blood) in adults and in 2024, AstraZeneca’s
LokelmaAstraZeneca
Lokelma net sales of $542 million. (over ~Rs 4,600 crore).
“The addition of SZC to our portfolio underscores our unwavering commitment to improving the care of patients with
chronic kidney disease
chronic kidney diseaseherapy area, we remain focused on expanding access to innovative treatments that empower healthcare professionals and enhance the quality of life for patients,” said Kirti Ganorkar, MD, Sun Pharmaceutical Industries Limited.
“With this partnership withSun Pharmaceutical Industries Limited
Sun Pharma
Sun Pharmapoised to significantly expand the reach of this vital therapy and help address the disease burden,” Praveen Rao Akkinepally, Country President and MD AstraZeneca Pharma India said.
Online Bureau
,
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!